French software company Dassault Systèmes will acquire life sciences artificial intelligence firm ArisGlobal for up to $2 billion (approximately 2.7 trillion won). Once the acquisition is completed, the combined entity is expected to build an AI platform spanning the entire therapeutic lifecycle, from drug discovery to post-market safety management.
Dassault Systèmes announced on the 1st that it signed a definitive agreement to acquire ArisGlobal on the 23rd of last month (local time) in Vélizy-Villacoublay, France. Under the terms, approximately $1.8 billion (approximately 2.5 trillion won) will be paid in cash at closing, with up to $200 million (approximately 270 billion won) in additional contingent payments over the coming years based on ArisGlobal’s achievement of AI-related revenue targets. The acquisition will be fully funded with cash on hand.
The transaction was unanimously approved by Dassault Systèmes’ board of directors. Subject to regulatory approvals and customary closing conditions, the deal is expected to close in the second half of this year.
ArisGlobal has provided enterprise software supporting patient safety management and regulatory affairs for biopharmaceutical, biotech, and medical device companies, as well as contract research organizations (CROs) and health authorities. The company serves more than 200 customers, including half of the world’s top 50 biopharmaceutical companies, and its platform processes over 12 million patient safety reports annually. ArisGlobal employs approximately 1,300 people worldwide and is expected to generate revenue of approximately $175 million (approximately 240 billion won) this year.
The company’s flagship NavaX AI platform automates complex workflows and improves data quality in the highly regulated life sciences industry, boosting productivity by more than 30%, according to the company. Dassault Systèmes plans to combine this platform with its virtual twin, modeling and simulation technologies, and clinical trial and manufacturing quality management solutions.
The core of the integrated platform envisioned by both companies is data connectivity. The goal is to link information generated across the entire therapeutic lifecycle—from molecular-level research data to clinical data and real-world treatment outcomes—into a single continuum, creating a “continuous evidence loop” that feeds back into drug development and safety evaluation. By combining clinical data and real-world evidence (RWE) with modeling and simulation capabilities, the companies aim to shorten drug development timelines and improve therapeutic safety and operational efficiency.
Pascal Daloz, CEO and Chairman of Dassault Systèmes, said, “The life sciences industry is transforming on the back of AI and precision medicine, while operational complexity and regulatory demands continue to grow. By combining real-world evidence with modeling and simulation capabilities, we will help customers bring safer, more innovative therapies to patients faster.”
Aman Wasan, CEO of ArisGlobal, said, “Through this combination, we will connect fragmented data from R&D to regulatory affairs, and fuse ArisGlobal’s AI technology with virtual twin, modeling, and simulation capabilities to build a platform that continuously learns across the entire therapeutic lifecycle.”
Dassault Systèmes expects the ArisGlobal acquisition to contribute to revenue growth and earnings per share (EPS) accretion from the first year following completion.